Key result
β-Blockers are no longer recommended as first-line therapy for primary hypertension because they are inferior to other antihypertensives and no better than placebo.
Physiological differences exist within the β-blocker class and compared to other antihypertensives, which may explain their diverse clinical effects in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
May inform antihypertensive selection in primary hypertension; leaves open whether physiological differences within the class affect outcomes.
Ripley et al. (2014) conducted a review in Hypertension. β-blockers vs. Other antihypertensives and placebo was evaluated. β-Blockers are no longer recommended as first-line therapy for primary hypertension because they are inferior to other antihypertensives and no better than placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: